Kimihiko Ito

Kimihiko Ito

Auto-generated profile, based on publicly available information

Kimihiko Ito

Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JHJunzo Hamanishi
Junzo Hamanishi
NTNobuhiro Takeshima
Nobuhiro Takeshima
NKNoriyuki Katsumata
Noriyuki Katsumata
KUKimio Ushijima
Kimio Ushijima
TKTadashi Kimura
Tadashi Kimura
IKIkuo Konishi
Ikuo Konishi
PURPOSE: This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS: Eligible patients had platinum-resistant epithelial ovarian cancer, received ≤ 1 regimen after diagnosis of resistance, and had an Eastern Cooperative Oncology Group performance score of ≤ 1. Patients were randomly assigned 1:1 to nivolumab (240 mg once every 2 weeks [as one cycle]) or chemotherapy (GEM 1000 mg/m2 for 30 minutes [once on days 1, 8, and 15] followed by a week's rest [as one cycle], or PLD 50 mg/m2 once every 4 weeks [as one cycle]). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), overall response rate, duration of response, and safety. RESULTS: Patients (n = 316) were randomly assigned to nivolumab (n = 157) or GEM or PLD (n = 159) between October 2015 and December 2017. Median OS was 10.1 (95% CI, 8.3 to 14.1) and 12.1 (95% CI, 9.3 to 15.3) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.0; 95% CI, 0.8 to 1.3; P = .808). Median PFS was 2.0 (95% CI, 1.9 to 2.2) and 3.8 (95% CI, 3.6 to 4.2) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.5; 95% CI, 1.2 to 1.9; P = .002). There was no statistical difference in overall response rate between groups (7.6% v 13.2%; odds ratio, 0.6; 95% CI, 0.2 to 1.3; P = .191). Median duration of response was numerically longer with nivolumab than GEM or PLD (18.7 v 7.4 months). Fewer treatment-related adverse events were observed with nivolumab versus GEM or PLD (61.5% v 98.1%), with no additional or new safety risks. CONCLUSION: Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer.

12 September 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
XXXing Xin
Xing Xin
KIKimihiko Ito
Kimihiko Ito
ADArghya Dutta
Arghya Dutta
YKYoshimi Kubo
Yoshimi Kubo

11 August 2020 in Advanced Science
Verified
Journal Article
Open access
PDF file
ADArghya Dutta
Arghya Dutta
KIKimihiko Ito
Kimihiko Ito
ANAkihiro Nomura
Akihiro Nomura
YKYoshimi Kubo
Yoshimi Kubo
Identification of a low‐potential decomposition pathway for lithium peroxide (Li2O2) in nonaqueous lithium–oxygen (Li–O2) battery is urgently needed to ameliorate its poor energy efficiency. In this study, experimental data and theoretical calculations demonstrate that the recharge overpotential (ηRC) of Li–O2 battery is fundamentally dependent on the Li2O2 crystallization pathway which is intrinsically related to the microscopic structural properties of the growing crystals during discharge. The Li2O2 grown by concurrent surface reduction and chemical disproportionation seems to form two discrete phases that have been deconvoluted and the amount of Li2O2 deposited by these two routes is quantitatively estimated. Systematic analyses have demonstrated that, regardless of the bulk morphology, solution‐grown Li2O2 shows higher ηRC (>1 V) which can be attributed to higher structural order in the crystal compared to the surface‐grown Li2O2. Presumably due to a cohesive interaction between the electrode surface and growing crystals, the surface‐grown Li2O2 seems to possess microscopic structural disorder that facilitates a delithiation induced partial solution‐phase oxidation at lower ηRC (<0.5 V). This difference in ηRC for differently grown Li2O2 provides crucial insights into necessary control over Li2O2 crystallization pathways to improve the energy efficiency of a Li–O2 battery.

1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
HMHarunobu Matsumoto
Harunobu Matsumoto
MSMototsugu Shimokawa
Mototsugu Shimokawa
KNKaei Nasu
Kaei Nasu
ASAyumi Shikama
Ayumi Shikama
TSTakaya Shiozaki
Takaya Shiozaki
NTNorihiro Teramoto
Norihiro Teramoto
We conducted a retrospective, multi-institutional, collaborative study to accumulate cases of neuroendocrine carcinoma of the endometrium, to clarify its clinicopathologic features, treatment, prognosis and prognostic factors to collate findings to establish future individualized treatment regimens. To our knowledge, this is the largest case study and the first study to statistically analyze the prognosis of this disease. At medical institutions participating in the Kansai Clinical Oncology Group/Intergroup, cases diagnosed at a central pathologic review as neuroendocrine carcinoma of the endometrium between 1995 and 2014 were enrolled. We retrospectively analyzed the clinicopathologic features, treatment, prognosis and prognostic factors of this disease. A total of 65 cases were registered from 18 medical institutions in Japan. Of these, 42 (64.6%) cases were diagnosed as neuroendocrine carcinoma of the endometrium based on the central pathological review and thus included in the study. Advanced International Federation of Gynecology and Obstetrics stages (stage III and IV) and pure type small cell neuroendocrine carcinoma cases had a significantly worse prognosis. Upon multivariate analysis, only histologic subtypes and surgery were significant prognostic factors. Pure type cases had a significantly worse prognosis compared to mixed type cases and complete surgery cases had a significantly better prognosis compared to cases with no or incomplete surgery. Our findings suggest that complete surgery improves the prognosis of neuroendocrine carcinoma of the endometrium. Even among cases with advanced disease stages, if complete surgery is expected to be achieved, clinicians should consider curative surgery to improve the prognosis of neuroendocrine carcinoma of the endometrium.

1 August 1994 in Transfusion
Verified
Journal Article
Closed access
PDF file
HYH. Yoshida
H. Yoshida
KIK. Ito
K. Ito
TKT. Kusakari
T. Kusakari
KIK. Ida
K. Ida
YIY. Ihara
Y. Ihara
MMM. Matsumura
M. Matsumura

23 July 2018 in RSC Advances
Verified
Journal Article
Open access
PDF file
CSChulho Song
Chulho Song
KIKimihiko Ito
Kimihiko Ito
OSOsami Sakata
Osami Sakata
YKYoshimi Kubo
Yoshimi Kubo
The Li–O 2 electrochemical reaction involving the formation and decomposition of crystalline Li 2 O 2 was clearly demonstrated by using an operando synchrotron-based XRD in a transmission mode and a special airtight LAB cell.